Sequential Intraarterial-Intravenous PRRT Shows Promise for Liver NETs

A prospective trial in 10 patients with liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors tested a personalized schedule combining intraarterial and intravenous Lu-DOTATATE administration. The trial reported that intraarterial delivery was feasible in all patients, produced over 3-fold higher radiation dose and 86% greater median uptake in liver lesions compared with intravenous administration, and was generally well tolerated with one severe adverse event unrelated to the administration route. Partial response rates were 67% at 3 months and 87% at 6 months according to RECIST and volumetric criteria.

Most relevant for: Patients with progressive, nonresectable, liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors expressing somatostatin receptors.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.